Hebei Senlang Biotechnology Inc., Ltd.

This study tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with a type of blood cancer (B-ALL) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cells. The goal …

This early study is testing a personalized cell therapy for people with ulcerative colitis that hasn't responded to standard treatments. Doctors will collect immune cells from 12 participants, modify them in a lab to target the disease, and then infuse them back. The main goal is…